Nonalcoholic fatty liver disease after liver transplant

Akshay Shetty; Fanny Giron; Mukul K. Divatia; Muhammad I. Ahmad; Sudha Kodali; David Victor

doi:10.14218/JCTH.2020.00072

Nonalcoholic fatty liver disease after liver transplant

Akshay Shetty, Fanny Giron, Mukul K. Divatia, Muhammad I. Ahmad, Sudha Kodali, David Victor

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease in the world. The rising prevalence of nonalcoholic steatohepatitis (NASH) has led to a 170% increase in NASH cirrhosis as the listing indication for liver transplantation from 2004 to 2013. As of 2018, NASH has overtaken hepatitis C as an indication for liver transplantation in the USA. After liver transplantation, the allograft often develops recurrent NAFLD among patients with known NASH cirrhosis. In addition to recurrent disease, de novo NAFLD has been reported in patients with other indications for liver transplantation. In this review, we will discuss the risk factors associated with recurrent and de novo NAFLD, natural course of the disease, and management strategies after liver transplantation.

Original language	English (US)
Pages (from-to)	428-435
Number of pages	8
Journal	Journal of Clinical and Translational Hepatology
Volume	9
Issue number	3
DOIs	https://doi.org/10.14218/JCTH.2020.00072
State	Published - 2021

Keywords

De novo NAFLD
De novo NASH
Nonalcoholic fatty liver disease
Nonalcoholic steatohepatitis
Posttransplant
Recurrent NAFLD
Recurrent NASH

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.14218/JCTH.2020.00072

Cite this

@article{ea96a059765e4178bb5cf822931362e3,

title = "Nonalcoholic fatty liver disease after liver transplant",

abstract = "Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease in the world. The rising prevalence of nonalcoholic steatohepatitis (NASH) has led to a 170% increase in NASH cirrhosis as the listing indication for liver transplantation from 2004 to 2013. As of 2018, NASH has overtaken hepatitis C as an indication for liver transplantation in the USA. After liver transplantation, the allograft often develops recurrent NAFLD among patients with known NASH cirrhosis. In addition to recurrent disease, de novo NAFLD has been reported in patients with other indications for liver transplantation. In this review, we will discuss the risk factors associated with recurrent and de novo NAFLD, natural course of the disease, and management strategies after liver transplantation.",

keywords = "De novo NAFLD, De novo NASH, Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Posttransplant, Recurrent NAFLD, Recurrent NASH",

author = "Akshay Shetty and Fanny Giron and Divatia, {Mukul K.} and Ahmad, {Muhammad I.} and Sudha Kodali and David Victor",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s).",

year = "2021",

doi = "10.14218/JCTH.2020.00072",

language = "English (US)",

volume = "9",

pages = "428--435",

journal = "Journal of Clinical and Translational Hepatology",

issn = "2225-0719",

publisher = "Xia & He Publishing Limited",

number = "3",

}

TY - JOUR

T1 - Nonalcoholic fatty liver disease after liver transplant

AU - Shetty, Akshay

AU - Giron, Fanny

AU - Divatia, Mukul K.

AU - Ahmad, Muhammad I.

AU - Kodali, Sudha

AU - Victor, David

PY - 2021

Y1 - 2021

N2 - Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease in the world. The rising prevalence of nonalcoholic steatohepatitis (NASH) has led to a 170% increase in NASH cirrhosis as the listing indication for liver transplantation from 2004 to 2013. As of 2018, NASH has overtaken hepatitis C as an indication for liver transplantation in the USA. After liver transplantation, the allograft often develops recurrent NAFLD among patients with known NASH cirrhosis. In addition to recurrent disease, de novo NAFLD has been reported in patients with other indications for liver transplantation. In this review, we will discuss the risk factors associated with recurrent and de novo NAFLD, natural course of the disease, and management strategies after liver transplantation.

AB - Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease in the world. The rising prevalence of nonalcoholic steatohepatitis (NASH) has led to a 170% increase in NASH cirrhosis as the listing indication for liver transplantation from 2004 to 2013. As of 2018, NASH has overtaken hepatitis C as an indication for liver transplantation in the USA. After liver transplantation, the allograft often develops recurrent NAFLD among patients with known NASH cirrhosis. In addition to recurrent disease, de novo NAFLD has been reported in patients with other indications for liver transplantation. In this review, we will discuss the risk factors associated with recurrent and de novo NAFLD, natural course of the disease, and management strategies after liver transplantation.

KW - De novo NAFLD

KW - De novo NASH

KW - Nonalcoholic fatty liver disease

KW - Nonalcoholic steatohepatitis

KW - Posttransplant

KW - Recurrent NAFLD

KW - Recurrent NASH

UR - http://www.scopus.com/inward/record.url?scp=85109674363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85109674363&partnerID=8YFLogxK

U2 - 10.14218/JCTH.2020.00072

DO - 10.14218/JCTH.2020.00072

M3 - Review article

AN - SCOPUS:85109674363

SN - 2225-0719

VL - 9

SP - 428

EP - 435

JO - Journal of Clinical and Translational Hepatology

JF - Journal of Clinical and Translational Hepatology

IS - 3

ER -

Nonalcoholic fatty liver disease after liver transplant

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this